Investors

Media

Welcome to the new Regeneron Newsroom. This newsroom is designed to provide members of the media with easy access to up-to-date information about the Company. If you are a reporter with a question about Regeneron, please call our Media Line at (914) 847-7800.

For an e-mail response to questions about Regeneron, please contact us at media@regeneron.com.



Upcoming Events

Feb 16, 2012
8:30 AM ET
Webcast Regeneron Pharmaceuticals Q4 and Year End Earnings Conference Call


View all releases Recent Press Releases

Jan 26, 2012 Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
Jan 3, 2012 Regeneron Announces Presentation at the 30th Annual J. P. Morgan Healthcare Conference
Jan 3, 2012 Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
Jan 2, 2012 Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
Dec 5, 2011 Two Year Results of Phase 3 Studies with EYLEA™ (aflibercept) Injection in wet AMD Show Sustained Improvement in Visual Acuity
Dec 1, 2011 Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
Nov 28, 2011 Regeneron and Bayer Initiate Phase 3 Clinical Program for the Treatment of Wet Age-Related Macular Degeneration in China
Nov 23, 2011 Regeneron Announces Upcoming Investor Conference Presentations
Nov 22, 2011 Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
Nov 21, 2011 Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors


Close
Form content here please :)